Assessment of Eplerenone effects on the imaging findings in acute central serous chorioretinopathy: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191116045458N1

Enrollment

Registered

2020-05-12

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute central serous chorioretinopathy. Central serous chorioretinopathy, unspecified eye

Interventions

Intervention 1: Intervention group: patients with definite diagnosis of acute CSCR will be under treatment of Eplerenone 25 mg BID treatment for 3 months. Intervention 2: Control group: will get place

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients that are referred to khatam eye hospital emergency room or clinics with the definite first episode of acute CSCR diagnosis with decreased visual acuity or metamorphopsia for less than 3 months No history of intraocular diseases No contraindication for eplerenone use (renal, heart or liver failure, pregnancy, breast feeding, K serum level more than 5 mg/dl, ACEI ,ARB or k-sparing diuretic use, hypertention,type 2 DM with microalbuminuria, use of azoles and clarithromycin).

Exclusion criteria

Exclusion criteria: any finding making CSCR diagnosis suspicious during treatment detection of any intraocular disease during treatment detection of any contraindication of Eplerenone during treatment

Design outcomes

Primary

Measure	Time frame
Choroidal perfusion. Timepoint: Before starting treatment, 1 month later and 3 months later. Method of measurement: According to parameters including subfoveal choroidal thickness, vessel density and flow rate in superficial , deep and choriocapillary level in 3mm center of macula.	—

Secondary

Measure	Time frame
Best corrected visual acuity. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Examination by optometrist.;Central macula thickness. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Subretinal fluid height. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Optic nerve head perfusion. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Vessel density flow index in OCT Angiography.	—

Measure

Time frame

Best corrected visual acuity. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Examination by optometrist.;Central macula thickness. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Subretinal fluid height. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Optic nerve head perfusion. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Vessel density flow index in OCT Angiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhodsieh Zamani

Mashhad University of Medical Sciences

ZamaniGH@mums.ac.ir+98 51 3728 1401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026